26/04/2024  21:59:17 Diferencia +0.380 Volumen Bid21:59:51 Ask21:59:51 Capitalización de mecado Dividendo A. P/E Ratio
27.375EUR +1.41% 404,068
Volumen de negocios: 11.07 millones
27.375Volumen de oferta: 1,000 27.570Tamaño/ Volumen/ Formato de Ask: 500 27.05 mil millonesEUR 0.40% -

Descripción de negocio

Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer’s products and services are designed to benefit people and improve the quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power.Bayer is committed to the principles of sustainable development and acts as a socially and ethically responsible corporate citizen.
 

Consejo de gestión & Consejo de supervisión

CEO
Bill Anderson
Consejo de gestión
Wolfgang Nickl, Heiko Schipper, Rodrigo Santos, Stefan Oelrich, Heike Prinz, Sebastian Guth
Consejo de supervisión
Prof. Dr. Norbert Winkeljohann, Heike Hausfeld, Dr. Paul Achleitner, Dr. rer. nat. Simone Bagel-Trah, Horst Baier, Dr. Norbert W. Bischofberger, André van Broich, Ertharin Cousin, Yasmin Fahimi, Dr. Barbara Gansewendt, Colleen A. Goggins, Francesco Grioli, Frank Löllgen, Kimberly Mathisen, Andrea Sacher, Claudia Schade, Heinz Georg Webers, Alberto Weisser, Michael Westmeier, Prof. Dr. med. Dr. h.c. mult. Otmar D. Wiestler
 

Datos de la empresa

Nombre: Bayer AG
Dirección: Kaiser-Wilhelm-Allee 1,D-51368 Leverkusen
Teléfono: +49-214-30-1
Fax: +49-214-30-81013
E-mail: info@bayer.com
Internet: www.bayer.de
Industria: Commodities
Sector: Chemicals
Subsector: -
Fin del año financiero: 31/12
Acciones de libre circulación: 68.44%
Fecha de OPI: 01/10/1953

Relación con inversores

Nombre: Oliver Maier
IR teléfono: +49-214-30-65742
IR-fax: +49-214-30-9665742
IR e-mail: oliver.maier@bayer.com

Calendario de la empresa

CW 18 | 29/04/2024 Ex-Dividend
CW 18 | 30/04/2024 Record Date
CW 18 | 02/05/2024 Dividend Payment
CW 20 | 14/05/2024 Interim Report 1st Quarter/3 Months
CW 32 | 06/08/2024 Interim Report 2nd Quarter/6 Months